Article

Beaufort’s Response to COVID-19

Beaufort CRO is closely monitoring the evolving circumstances surrounding COVID-19, including review of the latest state, national and international guidelines.

As this unprecedented situation continues to unfold, Beaufort remains committed to ensuring the continuity of all trials and related business while maintaining the health and safety of our employees and families, our clients and the patients they ultimately serve.

All of us recognize the critically important work you do, and the Beaufort Global Solutions Team is available to help support your needs as COVID-19 impacts your project planning and implementation activities.

In response to this crisis, Beaufort has instituted several measures including creation of a dedicated task force to continually evaluate and adapt current processes and protocols while maintaining the integrity and timeliness of all work. We have prepared our network of skilled resources to help sponsors safely meet their clinical trial planning, management, implementation and related regulatory and quality goals and deadlines.

Beaufort has also fully transitioned to flexible and remote work locations for staff. Since a large percentage of our team already provides remote-based services, the technologies and tools are in place to continue effective support of our clients. For example, study start-ups and data management have not been impacted as we utilize secure data transmission and communications through phone, email and video conferencing. We have also adopted creative solutions for other activities, such as pre-study and qualification visits, and instituted the steps necessary to assure deliverables are completed in an efficient and high-quality manner.

Beaufort is ready to work with you and help accelerate your medical innovations during these challenging times.

Our regular lines of communication remain open, and we encourage you to reach out to discuss any needs.

View all news & insights